Prof. Feng Yang, Ph.D.
E-mail：fyang@mailbox.gxnu.edu.cn
Research Interests:
Novel metal-based anti-tumor drugs and drug delivery system of protein
1）Mechanism of cell migration
2）DNA and Protein based design of novel metal-based anti-tumor drugs
3）Protein nanoparticle drug delivery system
Social service:
Member of editorial board for Current Pharmaceutical Design
Member of editorial board for The Open Medicinal Chemistry Journal
Member of editorial board for The Open Clinical Biochemistry Journal
Member of editorial board for Frontiers in Chemistry
Journal reviewerfor Mol Pharm、J Med Chem、Eur J Med Chem、J Inorg Biochem
Publications:
1. Yue JP, Zhang Y, Liang WG, Gou XW, Lee P, Liu H, Lyv WQ, Tang WJ, Yang F*, Liang H*, Wu XY*. In Vivo Epidermal Migration Requires Focal Adhesion Targeting of ACF7. Nature Communications. 2016, 7: 11692.
2. YL Ma, JP Yue, Y Zhang, CZ Shi, M Odenwald, WG Liang, Q Wei, A Goel, XW Gou, J Zhang, SY Chen, WJ Tang, JR Turner, F Yang*, H Liang*, HL Qin*, XY Wu*.ACF7 regulates inflammatory colitis and intestinal wound response by orchestrating tight junction dynamics. Nature Communications. 2017, 8: 15375.
3. Gou Y, Qi JX, Zhang Y, Jiang M, Zhou ZP, Wu XY, Yang F*, Liang H*. Developing anticancer copper(II) pro-drugs based on the nature of cancer cells and human serum albumin carrier IIA subdomain. Molecular Pharmaceutics. 2015, 12: 3597-3609.
4. Y Gou, Y Zhang, ZL Zhang, J Wang, ZP Zhou, H Liang*, F Yang*. Design of an anticancer copper(II) pro-drug based on the Lys199 residue of the active targeting human serum albumin nanoparticle carrier. Molecular Pharmaceutics. 2017, 14: 1861-1873.
5. Qi JX, Zhang Y, Gou Y, Zhang ZL, Zhou ZP, Wu XY, Yang F*, Liang H*. Developing an anti-cancer copper(II) pro-drug based on the His242 residue of the human serum albumin carrier IIA sub-domain. Molecular Pharmaceutics. 2016, 13: 1501−1507.
6. Qi JX, Gou Y, Zhang Y, XY Wu, Yang F*, H Liang*. HSA-based multi-drug delivery systems for combination therapy of three anticancer agents. Molecular Pharmaceutics. 2016, 13: 3098-105.
7. Yang F*, Yue J, Ma L, Ma Z, Li M, Wu X, Liang H*. Interactive associations of drug-drug and drug-drug-drug with IIA sub-domain of human serum albumin. Molecular Pharmaceutics. 2012, 9: 3259-65.
8. Wang J, Gou Y, Zhang Z, Yu P, Qi J, Qin Q, Sun H, Wu X, Liang H, Yang F*. Developing an Anticancer Copper(II) Multitarget Pro-Drug Based on the His146 Residue in the IB Subdomain of Modified Human Serum Albumin. Molecular Pharmaceutics, 2018, 15: 2180-2193.
9. Qi JX, Gou Y, Wu XY, T Wang, Yang F*. Developing anticancer ferric pro-drugs based on the N-donor residues of human serum albumin carrier IIA subdomain. Journal of Medicinal Chemistry, 2016, 59: 7497-511.
10. Gou Y, Zhang Z, Li D, Zhao L, Cai M, Sun Z, Li Y, Zhang Y, Khan H, Sun H, Wang T, Liang H*, Yang F*. HSA-based multi-target combination therapy: regulating drugs' release from HSA and overcoming single resistance in a breast cancer model. Drug Delivery, 2018, 25: 321-329.(IF=6.402)
Review:
1. Designing pro-drugs based on special residues of human serum albumin. Curr Top Med Chem. 2016, 16: 996-1008.
2. Evaluation of interactions between platinum-/ruthenium-based anticancer agents and human serum albumin: Development of HSA carrier for metal-based drugs. Curr Pharm Design. 2015, 21: 1848-61.
3. Interactive association of drugs binding to human serum albumin. Int J Mol Sci, 2014, 15: 3580-95. (IF=3.257)
Editorial Article:
1. HSA-based anti-inflammatory therapy: a new and improved approach. Future Med Chem. 2014, 6: 119-21.
2. HSA-based drug development and drug delivery systems. Curr Pharm Design. 2016, 21: 1784.
3. HSA IIA subdomain-based developing anticancer metal pro-drug: a new and improved approach. Future Med Chem. 2016, 8: 89-91.
